Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
JY.1.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XCRNSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.5.86NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
GJ.1.2.8NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
GE.1.5NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
HN.2.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.16.29NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FL.1.5NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
HK.11.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
GK.1.2.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
HK.3.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
GL.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
CM.8.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JN.1.1.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
HK.26NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
HK.3.14NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBC.1.6.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
GW.5.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
KC.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
HK.3.10NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FY.5.5.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.36.31NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.623NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.214.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.588NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.210NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
A.28NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.567NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
C.23NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
C.2.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.541NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.36.24NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.25NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.189NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.36.34NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.258NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.426NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.399NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.337NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
C.35NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.177.54NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.164NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
KY.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JN.2.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.392NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.377NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.5.3 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BB.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FY.3.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
HH.7NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used